Tvardi Therapeutics Ord Shs
TVRD4.690USD
-0.140-2.90%
Close 01/23, 16:00（ET）Quotes delayed by 15 min
43.99MMarket Cap
LossP/E TTM
More Details of Company
Tvardi Therapeutics Ord Shs Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Tvardi Therapeutics Ord Shs
Name
Name/Position
Position
Shareholding
Change
Dr. Susan Shiff, Ph.D.
Dr. Susan Shiff, Ph.D.
Independent Director
Independent Director
5.61K
--
Mr. Sujal A. Shah
Mr. Sujal A. Shah
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Wallace Hall
Mr. Wallace Hall
Independent Director
Independent Director
--
--
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Independent Director
Independent Director
--
--
Dr. Imran Alibhai, Ph.D.
Dr. Imran Alibhai, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
--
--
Mr. Dan Conn, J.D.
Mr. Dan Conn, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. John Kauh, M.D.
Dr. John Kauh, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey (Jeff) Larson, Ph.D.
Dr. Jeffrey (Jeff) Larson, Ph.D.
Senior Vice President - Research & Development
Senior Vice President - Research & Development
--
--
Dr. Yixin (Joseph) Chen, Ph.D.
Dr. Yixin (Joseph) Chen, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Susan Shiff, Ph.D.
Dr. Susan Shiff, Ph.D.
Independent Director
Independent Director
5.61K
--
Mr. Sujal A. Shah
Mr. Sujal A. Shah
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Wallace Hall
Mr. Wallace Hall
Independent Director
Independent Director
--
--
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Independent Director
Independent Director
--
--
Dr. Imran Alibhai, Ph.D.
Dr. Imran Alibhai, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Dec 9
Currency: USDUpdated: Tue, Dec 9
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Other revenue
1.32M
51.50%
Collaborative revenue
1.20M
46.63%
Clinical compound revenue
48.00K
1.87%
Commercial supply revenue
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Other revenue
1.32M
51.50%
Collaborative revenue
1.20M
46.63%
Clinical compound revenue
48.00K
1.87%
Commercial supply revenue
0.00
0.00%
Shareholding Stats
Updated: Wed, Dec 10
Updated: Wed, Dec 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sporos Bioventures LLC
8.93%
Solas Tvardi Sidecar LLC
8.11%
Slate Path Capital LP
7.51%
Tweardy (David John)
6.92%
DePinho (Ronald A)
6.67%
Other
61.86%
Shareholders
Shareholders
Proportion
Sporos Bioventures LLC
8.93%
Solas Tvardi Sidecar LLC
8.11%
Slate Path Capital LP
7.51%
Tweardy (David John)
6.92%
DePinho (Ronald A)
6.67%
Other
61.86%
Shareholder Types
Shareholders
Proportion
Corporation
19.23%
Individual Investor
17.56%
Hedge Fund
11.09%
Investment Advisor
11.02%
Investment Advisor/Hedge Fund
5.38%
Research Firm
0.51%
Bank and Trust
0.09%
Pension Fund
0.08%
Insurance Company
0.02%
Other
35.02%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
126
2.64M
22.11%
--
2025Q4
201
2.64M
28.19%
+318.90K
2025Q3
240
2.63M
28.09%
+211.56K
2025Q2
255
1.96M
20.86%
+381.35K
2025Q1
304
216.78K
14.22%
-690.19K
2024Q4
335
370.98K
24.35%
-475.57K
2024Q3
349
383.52K
25.18%
-554.07K
2024Q2
363
500.51K
32.96%
-507.31K
2024Q1
376
666.56K
43.91%
-330.38K
2023Q4
385
694.09K
45.87%
-306.90K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sporos Bioventures LLC
837.64K
8.93%
--
--
Oct 20, 2025
Solas Tvardi Sidecar LLC
761.29K
8.11%
--
--
Oct 20, 2025
Slate Path Capital LP
704.12K
7.51%
--
--
Sep 30, 2025
Tweardy (David John)
649.05K
6.92%
--
--
Oct 20, 2025
DePinho (Ronald A)
626.19K
6.67%
-151.45K
-19.48%
Sep 30, 2025
The Vanguard Group, Inc.
419.17K
4.47%
+20.76K
+5.21%
Sep 30, 2025
Tweardy (Samuel David)
315.66K
3.36%
-631.32K
-66.67%
Jul 07, 2025
BlackRock Institutional Trust Company, N.A.
305.94K
3.26%
+58.48K
+23.63%
Sep 30, 2025
Vifor (International), Ltd
205.47K
2.19%
-1.00
-0.00%
Apr 16, 2025
683 Capital Management LLC
176.03K
1.88%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Name
Proportion
Invesco Dorsey Wright SmallCap Momentum ETF
0.04%
Texas Capital Texas Small Cap Equity Index ETF
0.01%
iShares Russell 2000 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
Amplify Seymour Cannabis ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 ETF
0%
Schwab U.S. Small-Cap ETF
0%
ProShares UltraPro Russell2000
0%
View more
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.04%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Amplify Seymour Cannabis ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Ex-dividend Date
Type
Ratio
Apr 14, 2025
Merger
3→1
Date
Ex-dividend Date
Type
Ratio
Apr 14, 2025
Merger
3→1
